Tartarone Alfredo, Gallucci Giuseppina, Iodice Giovanni, Romano Giampiero, Coccaro Mariarosa, Vigliotti Maria Luigia, Mele Giuseppe, Matera Rosella, Di Renzo Nicola
Division of Medical Oncology and Haematology, Centro di Riferimento Oncologico della Basilicata, Strada Provinciale No. 8, 85028 Rionero in Vulture (PZ), Italy.
Int J Antimicrob Agents. 2004 Apr;23(4):412-3. doi: 10.1016/j.ijantimicag.2003.10.001.
We report an episode of severe bradycardia that occurred in a 49-year-old woman with fever and malignant jaundice during antibiotic therapy with linezolid, a new oxazolidinone with activity against Gram-positive cocci. In our case, the strict temporal dependence between bradycardia and linezolid therapy seems to provide strong evidence for a causal relationship. To our knowledge, this is the first report of linezolid-induced bradycardia. This adverse event confirms that the new antibiotic linezolid should be administered with caution in patient with jaundice and hepatic insufficiency.
我们报告了一例严重心动过缓事件，该事件发生在一名49岁患有发热和恶性黄疸的女性身上，当时她正在接受利奈唑胺（一种对革兰氏阳性球菌有活性的新型恶唑烷酮类抗生素）治疗。在我们的病例中，心动过缓和利奈唑胺治疗之间严格的时间相关性似乎为因果关系提供了有力证据。据我们所知，这是利奈唑胺引起心动过缓的首例报告。这一不良事件证实，对于黄疸和肝功能不全的患者，应谨慎使用新型抗生素利奈唑胺。
